Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept

Galactosialidosis is a rare lysosomal storage disease caused by a congenital defect of protective protein/cathepsin A (PPCA) and secondary deficiency of neuraminidase-1 and β-galactosidase. PPCA is a lysosomal serine carboxypeptidase that functions as a chaperone for neuraminidase-1 and β-galactosid...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Ther Methods Clin Dev
Asıl Yazarlar: Cadaoas, Jaclyn, Hu, Huimin, Boyle, Gabrielle, Gomero, Elida, Mosca, Rosario, Jayashankar, Kartika, Machado, Mike, Cullen, Sean, Guzman, Belle, van de Vlekkert, Diantha, Annunziata, Ida, Vellard, Michel, Kakkis, Emil, Koppaka, Vish, d’Azzo, Alessandra
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Gene & Cell Therapy 2020
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7782203/
https://ncbi.nlm.nih.gov/pubmed/33426146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtm.2020.11.012
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller